Glidum MF 2-1000 SR Tablet is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 1000 mg in a sustained-release formulation. It is indicated for the management of type 2 diabetes mellitus in patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake and utilization. The sustained-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Glidum MF 2-1000 SR Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Regular monitoring of blood glucose and renal function is recommended during therapy. This combination offers a synergistic approach to glycemic control, addressing both insulin secretion and insulin resistance.